GlassScriptPhysician profile
Robert F Onder
NPI 1164533295
$3,933.03
in general payments reported to CMS, 2019-2025
33 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.33 · 2020: $234 · 2021: $701 · 2022: $1,200 · 2023: $1,100 · 2024: $483 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,627 · Education: $71.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,627.48 |
| Education | $71.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $611.95 | 2019-2024 | Breztri, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $604.37 | 2020-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $532.75 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $297.01 | 2020-2024 | Dupixent |
| Genzyme Corporation | $268.72 | 2020-2023 | |
| Pfizer INC. | $250.15 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $221.31 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $165.35 | 2021-2022 | |
| Kaleo, INC. | $161.21 | 2019-2024 | Auvi-Q |
| Genentech USA, INC. | $146.77 | 2021-2023 | Xolair |
| Amgen INC. | $100.43 | 2022-2025 | Tezspire |
| Optinose US, INC. | $79.62 | 2021-2022 | |
| Pharming Healthcare, INC. | $72.03 | 2022-2023 | Ruconest |
| Aimmune Therapeutics, INC. | $70.75 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $65.37 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $64.10 | 2021-2023 | Belsomra |
| Grifols USA, LLC | $53.34 | 2022-2023 | Xembify |
| Leo Pharma INC. | $44.08 | 2022-2023 | Adbry |
| Alk-Abello, INC | $35.17 | 2019-2021 | |
| Biocryst US Sales Co., LLC | $18.95 | 2022 | |
| Bio Products Laboratory USA, INC. | $18.65 | 2022 | |
| Hikma Pharmaceuticals USA | $13.75 | 2023 | Ryaltris |
| Eyevance Pharmaceuticals LLC | $13.70 | 2021 | |
| Circassia INC. | $12.10 | 2019 | |
| Allergan, INC. | $11.40 | 2020 |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Onder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.